Pirfenidone, and other broad spectrum compounds that modulate the TGFβ superfamily show promise for treating fibrosis, and pirfenidone is an approved treatment in several countries for mild to moderate idiopathic pulmonary fibrosis. Here, TGFB1 is linked to pulmonary fibrosis.